Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- LDP Group to Make New Rules on Online OTC Drug Sales in the Diet Session, Consider Lawmaker-Sponsored Bill
January 22, 2013
- PAFSC’s 2nd Committee to Discuss GSK’s CLL Treatment Arzerra on January 31
January 21, 2013
- MHLW Mulling Measure to Encourage Welfare Recipients to Use Generics
January 21, 2013
- How Will Party’s Return Affect Healthcare and Drug Policy? LDP Back in Power for First Time in 3 Years
January 17, 2013
- MHLW to Launch Panel by Jan.-End to Discuss New Rule for Online OTC Drug Sales after Top Court Ruling
January 16, 2013
- MHLW to Make HPV, Hib, and Pneumococcal Vaccines Mandatory, Excluding Them from the FY2012 Extra Budget
January 16, 2013
- At Request of JMA, Pharmacists to Be Required to Confirm that Buyers of Switch OTC Version of Epadel Had Medical Exam Before Purchase
January 15, 2013
- Supreme Court OKs Online Sales of OTC Drugs, Rejects Govt Appeal
January 15, 2013
- MHLW Calls for Preventive Measures against Accidental Ingestion of Pharmaceutical Products by Children
January 15, 2013
- Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
- MHLW Revises GCP Ordinance, Pushes Clinical Trials with Simple Contract Procedures
January 11, 2013
- PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
- MHLW’s Revised Budget Request for FY2013 under LDP for Innovation-Related Spending 40% Less than under DPJ
January 11, 2013
- MHLW Approves 2 Switch OTC Versions of Epadel
January 7, 2013
- MHLW Survey Finds Nearly 10% of Doctors Who Prescribe Prazaxa Are Unaware of Warnings in Blue Letter
December 28, 2012
- MHLW Compiling Database of Drug Approvals Overseas
December 28, 2012
- PMDA Review Period Reduced for Both Priority, Standard Products
December 28, 2012
- 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
- MHLW Approves 23 Products Including Toviaz
December 26, 2012
- LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…